Gene expression profiling in breast cancer: A clinical perspective

Abstract

Gene expression profiling tests are used in an attempt to determine the right treatment for the right person with early-stage breast cancer that may have spread to nearby lymph nodes but not to distant parts of the body. These new diagnostic approaches are designed to spare people who do not need additional treatment (adjuvant therapy) the side effects of unnecessary treatment, and allow people who may benefit from adjuvant therapy to receive it. In the present review we discuss in detail the major diagnostic tests available such as MammaPrint dx, Oncotype dx, PAM50, Mammostrat, IHC4, MapQuant DX, Theros-Breast Cancer Gene Expression Ratio Assay, and their potential clinical applications.

Genomic profile of breast cancer: cost–effectiveness analysis from the Spanish National Healthcare System perspective

“…benefit from adjuvant chemotherapy [17]. In addition, they represent a meaningful advance in the process of involving patients in the treatment decision making process [6].…”

“…Accurate risk classification is required to identify patients at high risk of recurrence [17]. The proportion of patients classified as low and high risk may differ according to the tool used [17], implying variations in treatment decisions that may influence clinical and economic outcomes.…”

“…The proportion of patients classified as low and high risk may differ according to the tool used [17], implying variations in treatment decisions that may influence clinical and economic outcomes.…”

“…Genetic profiling could lead to better resource allocation, reduce unnecessary chemotherapy costs, and increase QoL [17]. Therefore, comparison of risk recurrence classification methods is essential for decision making [19].…”

Using High-Throughput Transcriptomic Data for Prognosis: A Critical Overview and Perspectives

“…[1][2][3][4][5] have not provided significant advance over prognosis based on classical clinical indicators (6), even though the acute need for improved prognostic tools was fully recognized and extensively addressed with several approved and commercially available products (see reviews for breast cancer in ref. 7, and for glioblastoma in refs. 8,9).…”